Search

Displaying results 1451 - 1460 of 8575 in total
  1. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    Therefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients. … [A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress.

  2. Drug

    Clonidine

    go.drugbank.com/drugs/DB00575
    ApprovedInvestigational

    [L7237,L54536,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237] … Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD.

  3. Target

    2-Cys peroxiredoxin

    go.drugbank.com/bio_entities/BE0009251
    TargetPlasmodium falciparum (isolate 3D7)

    Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively.

    Synonyms: 2-Cys Prx
  4. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    This drug has also been used for management of hypertriglyceridemia [L1503]. … A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study.

  5. Drug

    Neratinib

    go.drugbank.com/drugs/DB11828
    ApprovedInvestigational

    Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. … Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.

  6. Drug

    Etofamide

    go.drugbank.com/drugs/DB13258
    Approved

    Etofamide is used as an antiamoebic agent. Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].

  7. Drug

    Anastrozole

    go.drugbank.com/drugs/DB01217
    ApprovedInvestigational

    compared to earlier estrogen receptor modulators such as [tamoxifen]. … [A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863]

  8. Drug

    Tagraxofusp

    go.drugbank.com/drugs/DB14731
    ApprovedInvestigational

    [A253762] It was also approved by the European Commission on January 7, 2021.[L43712] … [A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is

  9. Drug

    Dibotermin alfa

    go.drugbank.com/drugs/DB11639
    ApprovedInvestigational

    Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.

  10. Drug

    Micafungin

    go.drugbank.com/drugs/DB01141
    ApprovedInvestigational

    It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.